Antagonist anti-CD40 antibody CHIR-12.12 causes tumor regression and prolongs survival in multiple myeloma xenograft models.

被引：0
|
作者：
Long, L [1 ]
Tong, X [1 ]
Patawaran, M [1 ]
Aukerman, L [1 ]
Jallal, B [1 ]
Luqman, M [1 ]
机构：
[1] Chiron Corp, Emeryville, CA 94608 USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
10.1182/blood.V104.11.4888.4888
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4888
引用
收藏
页码：304B / 304B
页数：1
相关论文
共 50 条
  • [21] ANTI-CD40 ANTIBODY-BINDING MODULATES HUMAN MULTIPLE-MYELOMA CLONOGENICITY IN-VITRO
    TONG, AW
    ZHANG, BQ
    MUES, G
    SOLANO, M
    HANSON, T
    STONE, MJ
    BLOOD, 1994, 84 (09) : 3026 - 3033
  • [22] The humanized Anti-CD40 antibody SGN-40 inhibits tumor growth in LAGκ-1A, a CD40+ mouse model of human multiple myeloma.
    Campbell, Richard A.
    Gordon, Melinda S.
    Sanchez, Eric
    Chen, Haiming
    Turker, Lauren
    Trac, Olivia
    Li, Mingjie
    Pang, Shen
    Bonavida, Benjamin.
    Said, Jonathan
    Drachman, Jonathan G.
    Berenson, James R.
    BLOOD, 2006, 108 (11) : 1000A - 1000A
  • [23] ANTI-CD40 ANTIBODY-BINDING MODULATES HUMAN MULTIPLE-MYELOMA CLONOGENICITY IN-VITRO
    TONG, AW
    SU, D
    MUES, G
    SOLANO, M
    STONE, MJ
    BLOOD, 1994, 84 (10) : A170 - A170
  • [24] Phase I trial of a humanized anti-CD40 monoclonal antibody (SGN-40) in the treatment of multiple myeloma.
    Hussein, MA
    Berenson, JR
    Niesvizky, R
    Munshi, NC
    Anderson, KC
    Ryan, KL
    Baumgartner, KT
    Miller, DM
    Drachman, JG
    McDonald, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 580S - 580S
  • [25] A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma
    Bensinger, William
    Maziarz, Richard T.
    Jagannath, Sundar
    Spencer, Andrew
    Durrant, Simon
    Becker, Pamela S.
    Ewald, Brett
    Bilic, Sanela
    Rediske, John
    Baeck, Johan
    Stadtmauer, Edward A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 159 (01) : 58 - 66
  • [26] ASKP1240, a Fully Human Anti-CD40 Monoclonal Antibody, Prolongs Pancreatic Islet Allograft Survival in Nonhuman Primates
    Watanabe, M.
    Yamashita, K.
    Suzuki, T.
    Kamachi, H.
    Kuraya, D.
    Koshizuka, Y.
    Ogura, M.
    Yoshida, T.
    Aoyagi, T.
    Fukumori, D.
    Shimamura, T.
    Okimura, K.
    Maeta, K.
    Miura, T.
    Sakai, F.
    Todo, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 (08) : 1976 - 1988
  • [27] The telomerase template antagonist GRN163L in combination with chemotherapeutics reduces tumor volume in multiple myeloma xenograft models.
    Ertem, SA
    Wu, KD
    Ponomarev, V
    Chin, AC
    Moore, MAS
    BLOOD, 2005, 106 (11) : 971A - 971A
  • [28] A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma
    Hussein, Mohamad
    Berenson, James R.
    Niesvizky, Ruben
    Munshi, Nikhil
    Matous, Jeffrey
    Sobecks, Ronald
    Harrop, Kate
    Drachman, Jonathan G.
    Whiting, Nancy
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (05): : 845 - 848
  • [29] Dacetuzumab (SGN-40), a humanized anti-CD40 monoclonal antibody, has chemosensitization activity and improves gemcitabine efficacy in NHL xenograft models
    Lewis, Timothy
    McCormick, Renee
    Stone, Ivan
    Gerber, Hans-Peter
    Mbow, Brianna
    Whiting, Nancy
    Drachman, Jonathan
    Grewal, Igbal
    Law, Che-Leung
    CANCER RESEARCH, 2009, 69
  • [30] Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: Clinical implications
    Tai, YT
    Catley, LP
    Mitsiades, CS
    Burger, R
    Podar, K
    Shringpaure, R
    Hideshima, T
    Chauhan, D
    Hamasaki, M
    Ishitsuka, K
    Richardson, P
    Treon, SP
    Munshi, NC
    Anderson, KC
    CANCER RESEARCH, 2004, 64 (08) : 2846 - 2852
12345